12/18
08:07 am
tnya
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
High
Report
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
12/18
08:07 am
tnya
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $18.00 price target on the stock.
High
Report
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $18.00 price target on the stock.
12/17
07:32 am
tnya
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy [Yahoo! Finance]
High
Report
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy [Yahoo! Finance]
12/17
07:00 am
tnya
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
High
Report
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
12/16
04:39 pm
tnya
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 [Yahoo! Finance]
High
Report
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 [Yahoo! Finance]
12/16
04:30 pm
tnya
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024
High
Report
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024
11/25
12:17 pm
tnya
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Medium
Report
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
11/25
08:37 am
tnya
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy [Yahoo! Finance]
High
Report
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy [Yahoo! Finance]
11/25
08:30 am
tnya
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
High
Report
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
11/19
08:20 am
tnya
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) [Yahoo! Finance]
11/19
08:00 am
tnya
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
11/7
09:51 am
tnya
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its price target lowered by analysts at Chardan Capital from $20.00 to $18.00. They now have a "buy" rating on the stock.
Low
Report
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its price target lowered by analysts at Chardan Capital from $20.00 to $18.00. They now have a "buy" rating on the stock.
11/6
04:22 pm
tnya
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
11/6
04:05 pm
tnya
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
High
Report
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/3
06:19 am
tnya
Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]
High
Report
Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]
11/1
09:29 am
tnya
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation [Yahoo! Finance]
Low
Report
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation [Yahoo! Finance]
10/18
03:34 pm
tnya
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "outperform" rating re-affirmed by analysts at Leerink Partners.
Low
Report
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "outperform" rating re-affirmed by analysts at Leerink Partners.
10/18
03:34 pm
tnya
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "overweight" rating re-affirmed by analysts at Piper Sandler.
Low
Report
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "overweight" rating re-affirmed by analysts at Piper Sandler.
10/18
11:01 am
tnya
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $16.00 price target on the stock.
Low
Report
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $16.00 price target on the stock.
10/18
08:33 am
tnya
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
High
Report
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
10/17
04:43 pm
tnya
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM [Yahoo! Finance]
Medium
Report
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM [Yahoo! Finance]
10/17
04:30 pm
tnya
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
Medium
Report
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM